Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 9,382.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,379 shares of the biotechnology company's stock after purchasing an additional 11,259 shares during the quarter. International Assets Investment Management LLC's holdings in Sarepta Therapeutics were worth $1,097,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Montag A & Associates Inc. bought a new position in shares of Sarepta Therapeutics during the third quarter worth $30,000. Cary Street Partners Investment Advisory LLC boosted its position in shares of Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 154 shares during the last quarter. Fifth Third Bancorp boosted its position in shares of Sarepta Therapeutics by 1,215.8% during the fourth quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 924 shares during the last quarter. Hudson Capital Management LLC bought a new position in shares of Sarepta Therapeutics during the third quarter worth $206,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Sarepta Therapeutics by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,397 shares of the biotechnology company's stock worth $291,000 after acquiring an additional 1,176 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Trading Up 0.1 %

SRPT stock traded up $0.16 during trading on Tuesday, hitting $117.12. The company had a trading volume of 440,864 shares, compared to its average volume of 977,215. The firm has a market capitalization of $11.00 billion, a P/E ratio of -19.14 and a beta of 0.94. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $159.89. The company has a 50 day simple moving average of $126.18 and a 200-day simple moving average of $110.21. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company had revenue of $396.80 million for the quarter, compared to the consensus estimate of $387.18 million. During the same quarter last year, the firm posted ($1.24) EPS. The firm's revenue was up 53.6% compared to the same quarter last year. As a group, research analysts forecast that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SRPT shares. Evercore ISI upped their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an "in-line" rating in a research report on Tuesday, February 20th. TheStreet raised shares of Sarepta Therapeutics from a "d" rating to a "c-" rating in a research note on Monday, March 4th. Royal Bank of Canada upped their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an "outperform" rating in a research note on Thursday, February 29th. Barclays upped their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an "overweight" rating in a research note on Thursday, February 29th. Finally, Wedbush reaffirmed an "outperform" rating and set a $224.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $158.38.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Kathryn Jean Boor sold 761 shares of the firm's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Ian Michael Estepan sold 1,200 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the completion of the sale, the chief financial officer now owns 39,114 shares in the company, valued at $5,018,326.20. The disclosure for this sale can be found here. Insiders have sold a total of 22,096 shares of company stock worth $2,739,419 in the last three months. Corporate insiders own 7.40% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.